Voltage-gated calcium channels are involved in nociception in the CNS and in the periphery. N-type (Ca v 2.2) and T-type (Ca v 3.1, Ca v 3.2 and Ca v 3.3) voltage-gated calcium channels are particularly important in studying and treating pain and epilepsy.
Introduction
Sensory nerve conduction relies on the coordinated activation of a suite of ion channels to generate fast and accurate responses to mechanical, thermal and chemical stimuli. In the periphery, harmful signals are perceived by 'nociceptive' neurons and relayed centrally via voltage-activated ion channels (K v , Na v , Ca v ) and ligand-gated ion channels (TRP, K 2P , P2X) (Waxman and Zamponi, 2014) as part of the 'painsignalling cascade' (Gold and Gebhart, 2010) . In chronic pain, these pathways are characterized by hyperactivity (Waxman and Zamponi, 2014) , and the effects of noxious stimuli are enhanced (hyperalgesia) to the point where nonnoxious stimuli are painful (allodynia) (see Guo and Hu, 2014) . Voltage-gated calcium channels (VGCCs) involved in pain pathways are localized to dendrites of primary sensory neurons and contribute to integrate nociceptive stimuli at the spine by regulating the release of pro-nociceptive neurotransmitters, including substance P, calcitonin gene-related peptide and glutamate, at the presynaptic nerve terminus (Simms and Zamponi, 2014) . Therefore, modulating specific Ca v subtypes could be a promising way to treat chronic pain.
Five distinct voltage-gated calcium current types have been described in mammalian cells: L-(Ca v 1.1, 1.2, 1.3 and 1.4), P/Q-(Ca v 2.1), N-(Ca v 2.2), R-(Ca v 2.3) and T-(Ca v 3.1, 3.2, 3.3) types (Catterall et al., 2005) . Importantly, each Ca v subtype has distinct electrophysiological properties, tissue-specific localization and pharmacological profiles (Catterall et al., 2005) . N-type calcium channels have been a major focus of research because they are localized at the presynaptic terminals of sensory nerves in the dorsal horn of the spinal cord, where they play a critical role in pain signalling (Saegusa et al., 2001; Lee, 2014) . As a result, Ca v 2.2 channels are strongly implicated in a range of chronic pain conditions including neuropathic pain (pain caused by injury to the nervous system). Specific Ca v 2.2 channel inhibitors have clinical applications (Altier and Zamponi, 2004; Perret and Luo, 2009; Bourinet et al., 2014) , such as ω-conotoxin MVIIA (Ziconotide). Ziconotide selectively targets Ca v 2.2 channels and is used to effectively treat intractable chronic pain conditions (Pope and Deer, 2013) . However, due to its chemical nature, Ziconotide must be administered into the cerebrospinal fluid via the intrathecal route and has a relatively narrow therapeutic window (Pope and Deer, 2013) .
T-type calcium channels modulate neuronal excitability in the peripheral and central nervous systems, where they are linked to hyperexcitable states such as epilepsy, pain and tremor disorders like Parkinson's disease (Bourinet et al., 2005; Choi et al., 2007; Kim et al., 2001) . Previously characterized T-type calcium channels inhibitors, such as mibefradil and ethoximide, have analgesic properties, suggesting that T-type channels may be involved in pain signalling (Matthews and Dickenson, 2001; Todorovic et al., 2002; Flatters and Bennett, 2004; Wen et al., 2010) . Unfortunately, mibefradil and ethoximide target a wide range of voltagegated ion channels, including sodium, potassium and chloride channels (Chouabe et al., 1998; Nilius et al., 1998; Eller et al., 2000) .
To overcome this lack of specificity, small molecule T-type calcium channel inhibitors were designed and have been shown to provide analgesic effects in mouse models of inflammatory and neuropathic pain (Kraus et al., 2010; Reger et al., 2011; Bladen et al., 2015) . Of particular note is the analgesic, low MW compound TTA-A2, which is more potent against inactivated than closed or resting channels (IC 50 values of 100 and 10 μM at Ca v 3.1 respectively), indicating its effects on targets are state-dependent (Francois et al., 2013) . Based on these findings, N-and T-type calcium channels are of particular interest for the study and treatment of chronic pain (see recent reviews by Cheong and Shin, 2013; Lee, 2013; Sekiguchi and Kawabata, 2013; François et al., 2014; Lee, 2014; Simms and Zamponi, 2014) .
During the last 5 years, numerous reports have described small molecule Ca v 2.2 channel inhibitors as alternatives to Ziconotide (see review by Lee, 2014) . Regrettably, clinical development of the most promising of these small-molecules, Z160, a reformulated form of NP118809 (Zamponi et al., 2009 ) (compound 1, Figure 1 ), was discontinued after it failed to meet end points in phase II clinical trials (Eller et al., 2000) . Due to this and the need for effective and safe therapeutics for chronic pain, the development of new classes of smallmolecule Ca v channel antagonists is of significant interest.
The pharmacophore of Ca v 2.2-selective ω-conotoxin GVIA (McCleskey et al., 1987; Baell et al., 2004; Baell et al., 2006; Andersson et al., 2009; Duggan et al., 2009 ) has been carefully studied and has led to the identification of a series
Figure 1
Chemical structures of compounds 1 (Z160/NP118809), 2 (MONIRO-1) and 3 (NNC 55-0396) relevant to this study.
of compounds that block Ca v 2.2 channels in a concentrationdependent manner (Tranberg et al., 2012) .
We focused on developing low MW calcium channel inhibitors with enhanced biophysical properties including reversibility, voltage-and/or state-dependence. Compounds acting via these mechanisms can strongly inhibit channels upon membrane depolarization (Hondeghem and Katzung, 1984; Butterworth and Strichartz, 1990) by preferentially targeting the open and/or inactivated states over the resting state. Such compounds would facilitate inhibition of highfrequency firing or depolarised nerves that can predominate in chronic pain states and could act within a wider therapeutic window.
To develop these calcium channel inhibitors, we screened a small library of related derivatives, using FLIPR Tetra® highthroughput cellular screening system, for their ability to inhibit Ca v 2.2-mediated calcium responses in SH-SY5Y cells using the fluorescent indicator Calcium 4 dye (Molecular Devices, Sunnyvale, CA, USA) (Gleeson et al., 2015) . In this assay, MONIRO-1 (compound 2, Figure 1) Dai et al. (2008) . These cell lines co-express recombinant human Ca v α 2b δ-1 (M76559.1) and Ca v β 3a (NM_000725) auxiliary subunits (Dai et al., 2008) . Cells are plated onto 12 mm cover glass and incubated at 30°C, 5% CO 2 for 24-48 h prior to recording. In a separate series of experiments, HEK293T cells were transiently co-transfected with plasmid cDNAs encoding mouse Ca v 1.2 (provided by Dr D. Lipscombe, Addgene plasmid # 26572; Helton et al., 2005) Previous experiments using the maximal concentration of DMSO used, 0.1% at 100 μM, did not modulate VGCC currents in recording solution. Depolarization-activated calcium currents (I Ca ) were evoked from a holding potential of À80 mV, with a 135 ms (50 ms for T-type) voltage step to a test potential (determined from peak of I-V curve) applied every 10 s. When evaluating I Ca amplitude in the presence and absence of various compounds, test depolarizations of varying durations were applied at a frequency of 0.03-2 Hz, from a holding potential of À60, À80 or À100 mV to a test potential determined from an I-V relationship to elicit peak inward current. To examine the effects of pulse duration on MONIRO-1 block and recovery from block, pulses of either 45 or 135 ms for Ca v 2.2 (30 μM) or 15 or 50 ms for Ca v 3.1 (3 μM) were elicited at a frequency of 0.1 Hz (V h = À80 mV). Similarly, to study the frequency dependence of MONIRO-1 inhibition, test pulses (45 ms for Ca v 2.2 or 15 ms for Ca v 3.1) were elicited at rates of 0.03, 0.1 and 0.2 Hz for Ca v 2.2 (10 μM MONIRO-1) and 0.03, 0.1, 0.2, 1 and 2 Hz for Ca v 3.1 (3 μM MONIRO-1). To determine the time constants for activation and inactivation of macroscopic currents, we used a single exponential equation to fit the traces in control and after MONIRO-1 application.
Activation curves were measured from test pulses from À80 to +80 mV every 5 mV for Ca v 2.2 and Ca v 3.1 channels (V h = À80 mV) before and after MONIRO-1 application. Steady-state inactivation (SSI) curves were generated from various pre-pulse potentials (À120 to 0 mV for Ca v 2.2; À85 to À20 mV for Ca v 3.1) of 10 s (Ca v 2.2) or 1 s (Ca v 3.1).
Recovery from inactivation was examined using a doublepulse protocol, varying the time between a fully inactivating pre-pulse and the test pulse repeated every 15 s, using a concentration of MONIRO-1, which inhibits~50% of the current. Recovery data were best fit by a double exponential. Currents were filtered at 3 kHz and sampled at 10 kHz. Leak and capacitive currents were subtracted using a ÀP/4 pulse protocol. Data were stored digitally on a computer for further analysis.
Data analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All data reported as mean ± SEM. Data analysis and graphs were built using OriginPro (Origin Lab Corporation, North Hampton, MA, USA). Concentration-response curves were generated by plotting current in the presence of MONIRO-1 (I compound ) over current prior to application (I control ) versus a range of MONIRO-1 concentrations tested. Typically, four to six concentrations per channel were screened with five to nine cells per concentration. Concentration-response data were plotted using a rectangular hyperbola assuming a Hill coefficient of 1, using the following expression,
where IC 50 is the concentration at which half-maximal inhibition was observed. Steady-state activation and inactivation curves were generated using a modified Boltzmann equation,
where V m is the test potential, V 0.5 is the half-maximal activation potential and κa is the slope factor. SSA and SSI data were each recorded from five to seven individual experiments per channel examined. Recovery from inactivation curves were the results from five to six independent experiments where the complete set of recovery from inactivation time points were acquired. The data were fit using a double exponential of the following equation,
where τ is the fast and slow time constant, t is the recovery time and A is the amplitude of the fast and slow time constants. Statistical significance (P < 0.05) was determined using unpaired Student's t-tests or one-way ANOVA with Tukey's post hoc test.
Materials
Compound 2, N-(2-(4-fluorophenoxy)phenyl)-4-(3-guanidinopropoxy)benzamide hydrochloride, MONIRO-1, was synthesized from 2-(4-fluorophenoxy)aniline in four steps, as reported previously (Gleeson et al., 2015 158.7, 154.4, 151.0, 130.5, 130.4, 127.9, 127.6, 126.9, 125.0, 120.8 (d, J = 8. NMR (376 MHz, CD 3 OD): δ À120.6, purity >92%, determined by HPLC analysis (λ = 254 nm), all tests were performed using the same batch of compound. The positive control, compound 1 (Z160/NP118809) (Zikolova and Ninov, 1972; Zamponi et al., 2009) , was prepared by N-(3-dimethylaminopropyl)-N 0 -ethylcarbodiimide-assisted acylation of N-benzhydryl piperazine with 3,3-diphenylpropanoic acid. Control compound NNC 55-0396 dihydrochloride was provided by Alomone Labs (Jerusalem, Israel).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 .
Results

Selective inhibition of human N-and T-type calcium channel subtypes
Whole-cell calcium currents were elicited by depolarizing pulses at a frequency of 0.1 Hz from a holding potential of À80 mV. MONIRO-1 reversibly inhibited channel currents mediated by Ca v 3.2 (IC 50 1.7 ± 0.1 μM, n = 5-9 cells per concentration), Ca v 3.1 (IC 50 3.3 ± 0.3 μM, n = 5-6 cells per concentration), Ca v 3.3 (IC 50 7.2 ± 0.3 μM, n = 5 cells per concentration) and Ca v 2.2 (IC 50 34.0 ± 3.6 μM, n = 5-7 cells per concentration) (Figures 2 and 3A) . The effects of MONIRO-1 were further investigated on a panel of VGCCs. At 100 μM, MONIRO-1 had no apparent effect on Ca v 2.1 (n = 6) or Ca v 2.3 (n = 5) ( Figure 3B ) but inhibited Ca v 1.2 and Ca v 1.3-mediated currents by 46 ± 1% (n = 5) and 27 ± 1% (n = 5) respectively.
In comparison, Z160/NP118809 (Zamponi et al., 2009 ) inhibited Ca v 2.2-mediated currents with an IC 50 of 0.28 ± 0.02 μM (n = 5-6 cells per concentration), without affecting Ca v 3.1 currents (maximal concentration tested 1 μM, Table 1 ). Application of 10 μM NNC 55-0396, a T-type calcium channel inhibitor, inhibited hCa v 3.2 currents by 96 ± 3% (n = 5). Furthermore, Z160/NP118809 inhibited hERG channels with an IC 50 of 7.4 μM (Zamponi et al., 2009 ) whereas 100 μM MONIRO-1 did not inhibit hERG channel-mediated K + currents (Table 1) . Table 1 compares the IC 50 values obtained for MONIRO-1 inhibition of L-, P/Q-, N-, R-and T-type calcium channels and the hERG potassium channel, with that of the control compounds, Z160/NP118809 and NNC 55-0396, and other known N-and T-type calcium channel inhibitors where electrophysiology data were obtained across a large portion of the VGCC subtypes. The current inhibition properties varied between the different MONIRO-1-sensitive Ca v subtypes, so we analysed the interaction between MONIRO-1 and T-type (Ca v 3.1) and N-type (Ca v 2.2) calcium channels.
Differential modulation of N-and T-type calcium channels: dependence on frequency and holding potential
We examined the inhibitory characteristics of MONIRO-1 at different test pulse durations and frequencies on Ca v 2.2 ( Figure 4A , B) and Ca v 3.1 channels ( Figure 5A, B) , as representatives of the VGCC types targeted by MONIRO-1. Ca v 2.2 currents in response to shorter (45 ms) depolarizations were 1.5-times more sensitive to MONIRO-1 inhibition than those elicited by a longer (135 ms) pulse. Channels held open by the longer pulse also recovered more completely from block (82 ± 9%, n = 5) than those briefly opened (45 ms; 47 ± 3%, n = 5) ( Figure 4A ). In agreement with these findings, higher frequency stimulation of Ca v 2.2 channels rendered a population of channels that was more potently inhibited by MONIRO-1 (0.03, 0.1 and 0.2 Hz; Figure 4B ). At a frequency of 0.2 Hz, MONIRO-1 inhibited Ca v 2.2 current by 29 ± 1% (n = 5), whereas at 0.1 and 0.03 Hz, only 21 ± 1% (n = 5) and 16 ± 1% (n = 5) of the current amplitude was inhibited respectively. Interestingly, the effects of MONIRO-1 on Ca v 2.2 channels are in marked contrast to its effects on Ca v 3.1 channels ( Figure 5A, B) . In the case of Ca v 3.1 channels, pulse duration did not affect Ca v 3.1-mediated current inhibition (% block 15 ms: 43 ± 3%, n = 5; and 50 ms: 51 ± 7%, n = 5), recovery from inhibition (% recovery 15 ms: 95 ± 1.3%, n = 5; and 50 ms: 99 ± 0.8%, n = 5) or frequency dependence of block over the same range as those tested for Ca v 2.2 channels (% block at 0.2 Hz = 43 ± 1.5%, n = 5; 0.1 Hz = 42 ± 2.3%, n = 5; and 0.03 Hz = 44 ± 1.6%, n = 5). However, at faster rates of 1 and 2 Hz, there was a significant increase in MONIRO-1 block of Ca v 3.1 channels (% block at 1 Hz = 61.0 ± 1.5%, n = 6; and 2 Hz = 71.0 ± 2.0%, n = 5). This would increase threefold the affinity for channels firing at faster frequencies of 2 Hz compared with those firing at rates <0.2 Hz. To further explore the differential effects of MONIRO-1 on Ca v 2.2 and Ca v 3.1 channels, we investigated the effect of membrane holding potential on block of Ca v 2.2 and Ca v 3.1 channels. MONIRO-1 could more effectively block Ca v 2.2 channels at more depolarized potentials (block at À100 mV = 34 ± 1.8%; À80 mV = 43 ± 3.2%; and À60 mV = 77 ± 5.5%, n = 5). In contrast, block at all of the holding potentials tested did not affect the degree by which MONIRO-1 inhibited Ca v 3.1 channels (block at À100 mV = 41-± 0.5%; À80 mV = 46 ± 5.1%; and À60 mV = 43 ± 0.6%, n = 5) ( Figures 4C and 5C ). This result highlights the statedependent differences between MONIRO-1 inhibition of Ca v 2.2 and Ca v 3.1 channels.
Effects of MONIRO-1 on N-and T-type calcium channel activation, inactivation and recovery from inactivation
To identify any effects that MONIRO-1 may have on calcium current kinetics and to understand the mechanisms behind Cells were held at À80 mV and pulsed at 0.1 Hz to the voltage determined to elicit the peak inward current previously determined from an I-V protocol. The number of cells is indicated in parentheses.
Table 1
Comparison of IC 50 values obtained for MONIRO-1 inhibition of L-, P/Q-, N-, R-and T-type calcium channels and the hERG potassium channel, with control compounds Z160/NP118809 and NNC 55-0396 and other known N-and T-type calcium channel inhibitors
L-type (μM) P/Q-type (μM) N-type (μM) R-type (μM) T-type (μM) hERG (μM)
Z160/NP118809 (Zamponi et al., 2009) 
MONIRO-1 block of voltage-gated calcium channels
the enhanced inhibition at depolarised membrane potentials, we examined its effects at half-maximal concentrations on Ca v 2.2 and Ca v 3.1 activation and SSI ( Figures 4D and 5D ). Exposure to MONIRO-1 did not affect the voltage-dependence of activation of Ca v 2.2 or Ca v 3.1 channels (Table 2 ). However, there was a significant~10 mV hyperpolarizing shift in Ca v 2.2 SSI. An apparent decrease in the voltage-dependence of SSI was also seen. However, no significant changes were observed in Ca v 3.1 SSI in the presence of MONIRO-1 or voltagedependence of SSI. Channel activation and inactivation time constants were examined, with and without MONIRO-1, for Ca v 2.2 (30 μM) and Ca v 3.1 channels (3 μM). MONIRO-1 had no effect on either the activation or inactivation time constants of Ca v 2.2 channels (Table 2) . However, MONIRO-1 application increased both activation and inactivation time constants for Ca v 3.1 channels (Table 2) . Finally, we investigated the effect of MONIRO-1 on Ca v 2.2 and Ca v 3.1 channel recovery from inactivation. MONIRO-1 had no observed effect on Ca v 2.2 recovery from inactivation time constants or their relative contribution to either time constants (control τ fast = 0.22 ± 0.1 s, A fast = 57 ± 8.5%; τ slow = 2.8 ± 0.7 s, A slow = 45 ± 8.6%; MONIRO-1 τ fast = 0.14 ± 0.1 s, A fast = 43 ± 7.0%; τ slow = 2.4 ± 0.4 s, A slow = 58 ± 6.2%, n = 5 respectively). However, MONIRO-1 slowed recovery of Ca v 3.1 channels from inactivation by decreasing the relative contribution of the fast recovery time constant while increasing the contribution of the slow time constant (control τ fast = 0.051 ± 0.008 s, A fast = 80.1 ± 5.1%; τ slow = 0.20 ± 0.11 s, A slow = 21.8 ± 5.4%; MONIRO-1 τ fast = 0.026 ± 0.007 s, A fast = 29.6 ± 4.2%; τ slow = 0.33 ± 0.03 s, A slow = 70 ± 4.1%, n = 6; P < 0.05). Therefore, MONIRO-1 can inhibit Ca v 3.1 channels more efficiently at firing frequencies >1 Hz ( Figure 5B) , as indicated by the slowed recovery from inactivation and frequency dependence, such as those prevailing in hyperexcitable neurons (Cain and Snutch, 2010) .
Discussion
In this study, we examined the effects of an orthophenoxyanilide on the inhibition and biophysical properties of VGCCs. This ortho-phenoxyanilide, MONIRO-1, is a low Activation and SSI curves in the absence (control) and presence of 30 μM MONIRO-1. Activation curves were generated through indicated depolarizing test pulses (135 ms) from a holding potential of À80 mV, repeated every 10 s. For SSI curves, selected pre-pulse potentials (À120 to 0 mV in 5 mV increments for 10 s) were applied prior to a test pulse (135 ms) determined from the peak current, repeated every 15 s from a holding potential of À80 mV. (E) Recovery from inactivation in the absence (control) and presence of 30 μM MONIRO-1. A two-pulse protocol (Inset) was repeated every 15 s, where the time was varied between the first fully inactivating pulse and the test pulse (0-10 s). *P < 0.05, significantly different as indicated; n.s. = not significant; Student's t-test.
MW compound and was selected for its ability to inhibit VGCCs in a high-throughput calcium influx assay (Gleeson et al., 2015) . To ascertain its selectivity and mode of action, we examined its potency of block and biophysical properties on a variety of VGCCs. MONIRO-1 was shown to be an N-and T-type calcium channel inhibitor with advantageous biophysical properties, including state-and use-dependence. It specifically targets Ca v 3.2 and Ca v 2.2 channels, which have Activation and SSI curves in the absence (control) and presence of 3 μM MONIRO-1. Activation curves were generated through indicated depolarizing test pulses (50 ms) from a holding potential of À80 mV, repeated every 10 s. For SSI curves, selected pre-pulse potential values (À85 to À20 mV in 5 mV increments for 1 s) were applied prior to a test pulse (50 ms) determined from the peak current, repeated every 10 s from a holding potential of À80 mV. (E) Recovery from inactivation in the absence (control) and presence of 3 μM MONIRO-1. A two-pulse protocol (Inset) was repeated every 15 s, where the time was varied between the first fully inactivating pulse and the test pulse. *P < 0.05, significantly different as indicated; n.s. = not significant; Student's t-test.
Table 2
Comparison of activation and inactivation parameters between Ca v 2.2 and Ca v 3.1 channels before and after application of MONIRO-1 À34.4 ± 0.6 mV (7) V 0.5 inactivation À41.3 ± 0.7 mV (5) À52.9 ± 1.3 mV (5)* À53.5 ± 0.6 mV (6) À55.1 ± 0.6 mV (6) Slope factor 5.3 ± 0.6 (5) 10.2 ± 1.2 (5)* 4.4 ± 0.6 (6) 6.1 ± 0.5 (6) *P < 0.05 compared with control, Students t-test. Data presented as mean ± SEM and n is given in brackets. a Concentration chosen based on IC 50 of individual channel.
MONIRO-1 block of voltage-gated calcium channels been implicated in various pain pathways, and Ca v 3.1 channels, which are involved in cell signalling and epilepsy (Choi, 2013; Waxman and Zamponi, 2014) . Given that MONIRO-1 inhibits depolarization-activated calcium responses from SH-SY5Y cells (Gleeson et al., 2015) , we determined its efficacy and selectivity against several VGCCs expressed in HEK293 cells. After screening representative members of each VGCC family (L-, N-, P/Q-, R-and T-types), we established that MONIRO-1 preferentially inhibits T-type channels (Ca v 3) responded to high concentrations of MONIRO-1. hERG, a typical off-target channel for low MW compounds, was not modulated by MONIRO-1 at concentrations up to 100 μM. Subsequently, we characterized the mechanism of MONIRO-1 inhibition on its primary targets, N-and T-type calcium channels.
In the present study, MONIRO-1 inhibited Ca v 3.1 channels with an IC 50 of 3 μM, so we examined the mechanistic details of this inhibition. Many T-type calcium channel inhibitors have been identified in assays looking for inactivation state-dependent inhibitors. These studies have led to compounds that predominantly bind and alter SSI, including TTA-A2, A-1048400 and NNC 55-0396, unlike MONIRO-1, which does not affect SSI of Ca v 3.1 channels. MONIRO-1 (3 μM) significantly slowed both channel activation and inactivation kinetics, without discernible effects on either V 0.5act or V 0.5inact . MONIRO-1 slowed recovery of Ca v 3.1 from inactivation at rates >1 Hz, which was reflected as an increase in current inhibition at 1 and 2 Hz ( Figure 5B , E), suggesting that MONIRO-1 would preferentially target epileptic firing neurons over normal firing neurons. Taken together, the lack of effect of MONIRO-1 on other biophysical properties examined, including the lack of effect of holding potential, suggests that it acts by binding to prevent Ca v 3.1 channels from transitioning from a non-conducting state to the open state. Therefore, the prolonged recovery from inactivation caused by MONIRO-1 inhibition of Ca v 3.1-mediated currents is likely to be due to the slower dissociation of the compound from the open-blocked channels or due to its accelerating channel transitions into a slow inactivated channel conformation. A similar phenomenon has been observed for mibefradil inhibition of Ca v 2.1 channels (Timin et al., 2004) .
Ca v 3.1 channels are key players in the circuitry involved in sleep including the reticular thalamic nucleus, thalamic relay neurons and neocortical pyramidal cells (Chen et al., 2014) . Ca v 3.1 channels are highly expressed in thalamocortical neurons (Kim et al., 2001; Song et al., 2004) , where they initiate entry of these neurons into bursting mode -a typical activity mode in absence seizures (Cain and Snutch, 2013) . Consequently, Ca v 3.1 channels have been directly linked to absence of epilepsies (Kim et al., 2001) . Disease mutations in Ca v 3.2 channels have also been linked to both rat models and human idiopathic generalized epilepsy (Khosravani et al., 2005; Powell et al., 2009) , suggesting that inhibitors of both Ca v 3.1 and Ca v 3.2 channels could decrease neuronal firing induced by hyperactivity of these channels during epilepsy. Compound Z944, which has higher affinity for the inactivated state of T-type calcium channels over the resting state, reduced seizure activity in terms of time spent in seizure and the total number of seizures per hour (Tringham et al., 2012) . During burst firing, VGCCs repetitively open and close at frequencies of 5-10 Hz (Cain and Snutch, 2010 Considerable research into pain physiology has focused on voltage-gated N-and T-type calcium channels. Ca v 3.2 channels are expressed in peripheral sensory neurons, where they modulate pain processing by controlling dorsal root ganglion neuroexcitability (Carbone and Lux, 1984) . Ca v 2.2 channels are located at presynaptic terminals in the CNS, where they modulate neurotransmitter release and fast synaptic transmission (Wheeler et al., 1994) . MONIRO-1 inhibits Ca v 2.2 channels under resting state conditions with an IC 50 of~30 μM, which is approximately 10-fold higher than that observed the T-type channels. However, the effect of MONIRO-1 on Ca v 2.2 channels is enhanced at higher frequencies, where faster pacing of the channel increased inhibition. At frequencies as high as 0.2 Hz (the maximum tested), the apparent affinity increased to~20 μM, with no observable change to the time course of activation or inactivation of the channel ( Figure 4B and Table 2) .
Following this observation, we examined the potential state dependence of the activity of MONIRO-1. Short (45 ms) depolarizing test pulses produced greater inhibition of Ca v 2.2 channels as well as less recovery after washout compared with a longer (135 ms) test pulse, suggesting a possible decrease in affinity for the open and/or inactivated state ( Figure 4A ). MONIRO-1 had a pronounced effect on Ca v 2.2 channel SSI that was not paralleled in Ca v 3.1 channels ( Figure 4D ), along with strong dependence on holding potential. At À60 mV,~80% of the whole-cell current was inhibited compared with À100 mV where only~35% of the current was blocked ( Figure 4C ). Such a hyperpolarizing shift in SSI and the dependence on holding potential suggests that MONIRO-1 preferentially binds to the inactivated state of N-type calcium channels (Bean et al., 1983; Bean, 1984; Sanguinetti and Kass, 1984) . Interestingly, unlike its effect on T-type calcium channels, MONIRO-1 did not influence N-type calcium channel recovery from inactivation ( Figure 5E ), suggesting a distinct mode of action against the two channel families.
Nociceptive stimuli cause depolarization, calcium channel opening, intracellular [Ca 2+ ] increase and neuronal hyper-excitability, as shown by faster firing rates (Winquist et al., 2005) . Nociceptive stimuli reduce the effective open time and increase the frequency of channel opening (Winquist et al., 2005) . Sustained neuronal firing in pain syndromes increases cytosolic calcium levels in the dorsal horn and shifts calcium channels into the inactivated state. Therefore, drugs that target Ca v 2.2 channels are best suited to 'prefer' those channels in the inactivated state (predominant in pain syndromes), allowing normal neurotransmitter release signalled by these channels in neurons not in a pain state. A few compounds have recently reported to exhibit use-and/or state-dependent inhibition of calcium channels involved in pain signalling, including A-1048400 (Scott et al., 2012) (compound 3, Figure 1 ), Z160/NP118809 1 (Zamponi et al., 2009) and TROX-1 (Abbadie et al., 2010) . To explore MONIRO-1 inhibitory mechanism of Ca v 2.2, we examined stimulation conditions comparable with those occurring in the physiological setting. Given that Ca v 2.2 channels can potentially accumulate in the inactivated state in hyperactive pain state conditions (Winquist et al., 2005) , the selective effect of MONIRO-1 on channels in this state could be a valuable pharmacological property that would enable therapeutic targeting during neuropathic pain treatment. Frequency dependence and preference of MONIRO-1 for the inactivated Ca v 2.2 channels suggest that it or related compounds may prove useful in the prevention of highfrequency firing episodes, an important signalling mode occurring during pain transmission. Therefore, MONIRO-1 may preferentially inhibit channels in hyperexcitable states in pain-specific loci, leaving normally firing neurons unaffected (Liao et al., 2011) .
In conclusion, we have identified MONIRO-1 as a low MW antagonist of voltage-gated calcium channels with 10-to 100-fold higher affinity for Ca v 3.1, Ca v 3.2, Ca v 3.3 and Ca v 2.2 channels than other classes of VGCCs examined. MONIRO-1 is a valuable tool for the study of VGCCs because it inhibits N-and T-type calcium channels through distinct mechanisms. Given its state-and use-dependent inhibition of Ca v 2.2 channels (preferentially inhibits the inactivated state) and Ca v 3.1 channels (prohibiting channel transitions to the open state), while exhibiting frequency-dependent block of both channels, MONIRO-1 is a novel lead compound that could be used to develop Ca v channel blockers to treat VGCC pathologies, including neuropathic pain and epilepsy. MONIRO-1 shows a novel mechanism of block of hCav3.1 channels compared with previously described T-type calcium channel blockers, in that it slows channel activation and inactivation kinetics and traps channels at high-frequency firing (>1 Hz) from transitioning to the open state while not altering SSI. Prior to in vivo assessment of their analgesic potential, MONIRO-1 and analogues need to be characterized at other voltagegated ion channels in pain pathways, including Na v 1.7 and Na v 1.8 channels.
